Latest Biotech News

FDA approved Moderna’s mRNA influenza vaccine for older adults, positioning the shot as the first licensed flu vaccine using messenger RNA technology. The decision followed a contentious period in...

Supernus and Indivior agreed to combine in an all-stock deal valued at about $1.8 billion, creating a larger CNS platform spanning neurological and addiction programs. Under the terms, Indivior...

Braveheart Bio priced an upsized initial public offering on Nasdaq to take Hengrui’s cardio asset into Phase 3, marking the second time this year a U.S.-listed biotech emerged from Hengrui’s...

Attovia Therapeutics raised about $289 million in an upsized IPO to fund clinical development across its immunology and inflammation pipeline. The offering priced 17 million shares at $17 each,...

Natera submitted its Signatera MRD test to Japan’s PMDA as a companion diagnostic for muscle-invasive bladder cancer, supporting disease monitoring alongside Tecentriq in ctDNA-positive patients...

Icon announced a multi-year collaboration with Anthropic to deploy Claude for clinical trials, aiming to reduce operational bottlenecks that slow enrollment and study execution. Under the deal,...

Lilly’s oral GLP-1 Foundayo missed analysts’ expectations in Q2, but the company kept widening its injected tirzepatide lead with strong Mounjaro and Zepbound revenue growth. Novo reported...

Caris Life Sciences raised full-year guidance as Q2 revenue surged 45% on a jump in molecular profiling services, including new Medicare reimbursement for its Caris ChromoSeq whole-genome plus...

Gilead’s HIV prevention business exceeded $1 billion in quarterly sales for the first time, driven by Descovy’s daily pill growth and strong early uptake of Yeztugo. The company reported Q2 PrEP...

Twist Bioscience priced a $300 million public offering to fund R&D, manufacturing capacity expansion, and additional product offerings. The company set the share price at $96 and expects net...

FDA has approved Moderna’s mRNA influenza vaccine for older adults, marking the first licensed flu shot built using the technology. The decision follows a February “refusal-to-file” that halted...

Braveheart Bio priced an IPO designed to fund further development of a Hengrui-derived cardiovascular therapy, pushing the program into Phase 3. The company’s listing on Nasdaq comes as a second...

The FDA approved Takeda’s orexin receptor agonist for narcolepsy type 1, clearing the twice-daily treatment for a patient population defined by orexin neuron deficiency. The decision launches a...

Natera has submitted its Signatera molecular residual disease test to Japan’s PMDA for companion diagnostic approval in muscle-invasive bladder cancer. The filing is supported by data from...

Reuters reported that AstraZeneca and Bristol Myers Squibb are no longer in merger discussions, effectively ending deal speculation. The update follows earlier coverage claiming talks were...

Recursion and Genentech announced plans to co-develop a neuroscience small-molecule program after Genentech exercised the first validated target option from their AI-discovery collaboration....

Curative Insurance Company teamed up with Wondr Health to expand weight management and metabolic health support for its members. The collaboration is aimed at broadening coverage of structured...

Caris Life Sciences reported a 45% year-over-year jump in Q2 2026 revenue, driven primarily by molecular profiling services. The company also said it received its first Medicare reimbursement for...

Researchers tied to the National Institutes of Health’s Human Cancer Models Initiative unveiled a major expansion of patient-derived 3D tumor resources. The effort adds hundreds of next-generation...

With FDA clearing Takeda’s orexin agonist for narcolepsy type 1, sleep medicine is seeing a clearer shift toward mechanism-defined treatments rather than symptom-first approaches. The twice-daily...